华海药业回应美计划对药品征收关税：公司已经在进行全球化市场拓展

Core Viewpoint - The company acknowledges potential impacts from the U.S. imposing tariffs on pharmaceuticals, particularly on its exports, which primarily consist of formulations [1] Group 1: Company Operations - The company's products exported to the U.S. are mainly formulations, with a significant portion produced domestically and some manufactured locally in the U.S. [1] - In 2023, revenue from the U.S. region accounted for approximately 13% of the company's total revenue [1] Group 2: Response Measures - The company may need to explore adjustments in production processes to mitigate the effects of potential tariffs, given the competitive pricing environment in the U.S. market [1] - The company is evaluating whether its U.S. production base can accommodate alternative production methods, with the possibility of relocating production facilities being considered [1] - The company has been actively pursuing global market expansion, although the U.S. market for formulations currently shows greater profitability [1]